With over one billion people worldwide affected by obesity, the weight-loss drug market is hot. In 2024, the global market for anti-obesity medications (AOMs) surpassed $30 billion for the first time, marking a tenfold increase since 2020.
With breakthrough innovations on the horizon and billions in potential sales at stake, the weight-loss drug industry is rapidly becoming one of the most transformative and investable segments in healthcare.
So, with billions in potential sales and an increasingly crowded field, it could be an opportune time for investors to scoop up the shares of the following companies, which are doubling down on their efforts to dominate this high-growth sector.
This post originally appeared at StockNews.com.